Trigeminal neuralgia causes severe, lancinating facial pain and afflicts approximately 3% of individuals diagnosed with multiple sclerosis. Managing trigeminal neuralgia in MS remains a formidable clinical challenge because pharmacological therapies often prove ineffective or cause debilitating side effects. Consequently, clinicians frequently evaluate invasive options when standard drug regimens fail. Neurosurgical interventions offer viable pathways toward durable pain relief, yet clinical choices require careful balancing of therapeutic efficacy against procedural risks. Recent comprehensive evidence provides clear guidance regarding which neurosurgical techniques best serve this medically complex patient population.

Evaluating Trigeminal Neuralgia in MS and Surgical Challenges

Patients living with demyelinating disease experience secondary facial pain far more frequently than the general population. Multiple sclerosis lesions along the prepontine trigeminal root entry zone disrupt central sensory pathways and provoke explosive neuralgic paroxysms. However, neurovascular compression from adjacent arterial loops also commonly coexists with demyelinating plaques. This anatomical overlap creates substantial diagnostic uncertainty for treating physicians. Specifically, surgeons must determine whether central pontine demyelination or mechanical neurovascular pulsation drives the patient's acute pain paroxysms. High-resolution magnetic resonance imaging plays an indispensable role during preoperative assessments. Clinicians utilize targeted three-dimensional sequences to confirm contact between offending vessels and the sensory nerve root. Furthermore, advanced neuroimaging differentiates active inflammatory plaques from mechanical vascular compression. When oral medications fail to control unbearable facial pain, clinicians must stratify patients according to precise imaging findings and surgical candidacy. Choosing the appropriate neurosurgical strategy requires clear understanding of each procedure's initial success rate and long-term durability. Clinicians must weigh procedural invasiveness against anticipated clinical benefits to optimize outcomes for these fragile individuals. Moreover, disease-modifying therapies do not reliably mitigate neuropathic facial pain. Therefore, neurosurgical teams must intervene decisively when intractable symptoms severely diminish daily functioning and quality of life.

Microvascular Decompression: Efficacy and Neurological Risks

Microvascular decompression directly addresses mechanical vascular compression at the root entry zone. Surgeons meticulously mobilize aberrant cerebellar vessels away from the trigeminal root and insert inert synthetic pads. In multiple sclerosis patients with demonstrable neurovascular conflict, this craniotomy procedure yields exceptionally durable pain relief. Recent systematic review data confirm that microvascular decompression provides extended periods of complete freedom from pain. However, open posterior fossa surgery carries serious procedural risks that require careful evaluation. The systematic synthesis identified significant neurological morbidities, including cranial neuropathies, cerebrospinal fluid leaks, and one fatal outcome within the reviewed cohorts. In addition, diagnostic uncertainty persists regarding whether pain originates purely from neurovascular conflict or from underlying pontine demyelination. If underlying demyelination triggers the neuralgic discharges, vascular transposition may produce incomplete relief despite flawless technical execution. Consequently, neurosurgeons reserve posterior fossa decompression for robust candidates with unambiguous radiographic compression. Surgeons avoid invasive open craniotomies in frail individuals or patients lacking distinct vascular conflict. Cautious candidate selection ensures that the substantial durability of decompression outweighs its potential perioperative hazards. Furthermore, multidisciplinary teams must monitor systemic multiple sclerosis activity closely before scheduling open elective surgery. Postoperative recovery demands excellent physical resilience from patients.

Partial Sensory Rhizotomy: Durability and Complications

Partial sensory rhizotomy presents an effective alternative when neurosurgeons encounter no vascular conflict during exploration. Surgeons selectively section the outer sensory rootlets of the trigeminal nerve, thereby interrupting peripheral nociceptive signal transmission. Clinical investigations demonstrate remarkable initial efficacy, with immediate pain relief rates ranging from 95.3% to 100%. Furthermore, this procedure achieves notable long-term durability, showing recurrence-free intervals between 20.1 and 79 months. Therefore, partial rhizotomy warrants earlier consideration within the surgical algorithm for refractory cases lacking neurovascular compression. Nevertheless, the physical disruption of sensory fibers carries inherent clinical risks that clinicians must explain thoroughly. Selective nerve sectioning frequently induces permanent facial sensory deficits and corneal numbness. Most concerningly, published systematic data noted severe sensory dysfunction, including anesthesia dolorosa, in up to 7.5% of treated patients. Anesthesia dolorosa represents a distressing, intractable burning facial neuropathy that responds poorly to subsequent medical interventions. Surgeons must clearly communicate these sensory risks during preoperative counseling. Consequently, clinicians recommend partial sensory rhizotomy primarily for severe, treatment-resistant pain when non-destructive options cannot provide durable relief. Additionally, experienced neurosurgeons carefully calibrate the extent of nerve sectioning to minimize catastrophic sensory loss. Such technical precision helps preserve essential protective corneal sensation.

Percutaneous Ablative Modalities and Radiosurgical Outcomes

Percutaneous ablative techniques offer minimally invasive treatment pathways for patients who cannot tolerate open intracranial surgery. Interventional surgeons commonly utilize radiofrequency thermocoagulation, percutaneous balloon compression, or retrogasserian glycerol rhizotomy. These needle-based interventions achieve high initial pain control rates between 58% and 100%. In comparison, stereotactic gamma knife radiosurgery provides a totally noninvasive alternative that delivers focused ionizing radiation directly to the trigeminal cisternal segment. Radiosurgery yields initial pain reduction rates ranging from 52.7% to 97.3%. Moreover, radiosurgical series demonstrate that different radiation dosages, such as 80 Gy, provide comparable pain alleviation without significant variation. Both percutaneous ablation and radiosurgery demonstrate favorable safety profiles with minimal major surgical morbidity. However, the durability of pain relief remains suboptimal compared to open operative interventions. Pain recurrence typically emerges between 8 and 60 months following percutaneous ablation and between 7.4 and 74.5 months after radiosurgery. Fortunately, clinicians can safely repeat these minimally invasive interventions if paroxysmal facial pain returns. Therefore, elderly or medically frail individuals with severe demyelinating disease often choose these lower-risk options. Additionally, outpatient recovery times remain short, enabling rapid resumption of daily activities. These practical benefits provide substantial relief for vulnerable individuals.

Emerging Procedures and Strategic Multidisciplinary Care

Recent neurosurgical innovations continue to expand the therapeutic armamentarium for difficult cases. A notable 2025 study highlighted preliminary outcomes of arachnoid-trigeminal nerve release for demyelinating facial pain. Specifically, investigators observed that 75% of patients attained Barrow Neurological Institute pain scale score I at final follow-up. This novel microdissection technique gently frees the nerve root from restrictive arachnoid adhesions without causing severe mechanical injury. Meanwhile, optimizing overall outcomes requires cohesive collaboration between neurologists, pain specialists, and neurosurgeons. Clinical teams must conduct high-resolution neuroimaging to identify vascular loops and pontine plaque burdens before recommending surgical options. Furthermore, clinicians must evaluate patient age, physical functional score, and underlying multiple sclerosis disease stability. When neurovascular conflict is radiographically evident, microvascular decompression offers durable benefits but requires cautious patient selection. Conversely, percutaneous ablation and stereotactic radiosurgery serve as safe, repeatable choices regardless of plaque burden. Partial sensory rhizotomy provides valuable rescue therapy for refractory non-compressive pathology. Ultimately, structured prospective trials will establish standardized reporting and refine personalized surgical decision pathways for patients worldwide. Additionally, Indian neurosurgical centers increasingly implement these multidisciplinary algorithms to streamline patient management. Such coordinated care ensures timely intervention and preserves functional independence.

Frequently Asked Questions

Why is trigeminal neuralgia more complex to treat in multiple sclerosis?

Multiple sclerosis produces central demyelinating plaques along brainstem trigeminal pathways while frequently coexisting with mechanical neurovascular compression. This dual mechanism creates diagnostic uncertainty regarding the primary pain generator. Furthermore, demyelination impairs endogenous pain modulation, making facial neuralgia less responsive to standard oral medications and surgical interventions.

When should surgeons consider microvascular decompression for these patients?

Surgeons consider microvascular decompression when high-resolution preoperative magnetic resonance imaging demonstrates unequivocal neurovascular conflict. Candidates must possess good cardiopulmonary fitness to withstand posterior fossa craniotomy safely. Although microvascular decompression offers excellent durability, teams must exercise cautious patient selection due to procedural risks and potential persistent pain from demyelinating plaques.

How do percutaneous ablative techniques compare with radiosurgery?

Both percutaneous ablative procedures and gamma knife radiosurgery achieve initial pain control rates comparable to primary trigeminal neuralgia cohorts. Radiosurgery avoids invasive cannulation, whereas percutaneous techniques provide immediate relief. Although both modalities show lower long-term durability than open surgery, clinicians can safely repeat them with low complication rates.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Healthcare professionals must exercise independent clinical judgment and consult official drug labels, institutional protocols, and peer-reviewed literature prior to making patient care decisions. Refer to the latest local and national guidelines for clinical practice.

References

1. Kalyana A et al. The efficacy of surgical interventions for trigeminal neuralgia in multiple sclerosis: A systematic review. Neurosurg Rev. 2026 Oct 07. doi: 10.1007/s10143-026-04494-5. PMID: 42839184.
2. Broggi M, et al. Trigeminal neuralgia in multiple sclerosis: proposal of surgical flowchart and long-term outcome evaluation in a mono-institutional cohort. Neurol Sci. 2024;45(12):5891-5899.
3. Sohrabi M, et al. Efficacy and Challenges: Minimally Invasive Procedures for Trigeminal Neuralgia Treatment in Multiple Sclerosis - A Systematic Review and Meta-Analysis. Stereotact Funct Neurosurg. 2024;102(2):87-98.
4. Montano N, et al. Trigeminal Neuralgia in Multiple Sclerosis: A Critical Review of the Therapeutic Evidence and the Role of Cerebellopontine Angle Surgical Exploration. J Clin Med. 2026;15(16):5120.